← SUPERNUS PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $66.4m | $100.3m | $192.2m | $181.4m | $288.6m | $203.4m | $93.1m | $75.1m | $69.3m | $128.4m | |
| Prepaid Expense and Other Assets, Current | $3.0m | $6.5m | $8.9m | $11.6m | $18.7m | $27.0m | $15.8m | $16.7m | $36.1m | $65.3m | |
| Inventory, Net | $16.8m | $16.3m | $25.7m | $26.6m | $48.3m | $86.0m | $91.5m | $77.4m | $54.3m | $112.5m | |
| Assets, Current | $151.4m | $228.5m | $493.5m | $472.6m | $630.4m | $601.6m | $734.2m | $493.1m | $686.1m | $644.2m | |
| Property, Plant and Equipment, Net | $4.3m | $5.1m | $4.1m | $17.1m | $37.8m | $17.0m | $15.2m | $13.5m | $11.5m | $10.5m | |
| Goodwill | — | — | — | $0 | $77.9m | $117.5m | $117.0m | $117.0m | $117.0m | $124.9m | |
| Intangible Assets, Net (Excluding Goodwill) | $16.5m | $36.0m | $31.4m | $24.8m | $364.3m | $784.7m | $702.5m | $599.9m | $521.9m | $569.5m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $21.3m | $20.2m | $35.4m | $28.9m | $29.0m | $24.5m | $26.7m | |
| Other Assets, Noncurrent | $331k | $389k | $380k | $615k | $43.2m | $49.2m | $39.8m | $37.5m | $31.5m | $63.8m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $41.5m | $65.6m | $102.9m | $87.3m | $140.9m | $148.9m | $165.5m | $144.2m | $142.1m | $187.8m | |
| Accrued Liabilities, Current | $27.4m | $27.3m | $36.5m | $37.1m | $78.9m | $117.7m | $96.3m | $79.6m | $76.4m | $107.8m | |
| Assets | $309.6m | $424.5m | $977.8m | $1.2b | $1.5b | $1.7b | $1.7b | $1.3b | $1.4b | $1.5b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $2.8m | $3.8m | $6.5m | $6.8m | $8.3m | $6.9m | $10.6m | |
| Accounts Payable, Current | $8.1m | $6.8m | $3.2m | $10.1m | $6.1m | $9.3m | $10.5m | $2.0m | $4.6m | $2.7m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $30.4m | $28.6m | $41.3m | $36.0m | $33.2m | $27.4m | $30.4m | |
| Liabilities, Current | $80.7m | $123.0m | $161.4m | $160.6m | $245.1m | $315.4m | $688.0m | $290.2m | $292.4m | $338.2m | |
| Deferred Income Tax Liabilities, Net | — | — | — | $0 | $35.2m | $85.4m | $49.8m | $25.0m | $5.0m | $0 | |
| Other Liabilities, Noncurrent | $4.0m | $10.6m | $11.4m | $9.4m | $42.8m | $16.4m | $8.7m | $6.4m | $7.6m | $22.2m | |
| Deferred Tax Liabilities, Net | — | — | — | $0 | $35.2m | $85.4m | $49.8m | $25.0m | $5.0m | $0 | |
| Liabilities | $117.8m | $157.0m | $524.8m | $564.9m | $759.2m | $873.3m | $816.3m | $356.2m | $332.3m | $390.9m | |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, Issued | $50k | $51k | $52k | $53k | $53k | $53k | $54k | $55k | $56k | $57k | |
| Additional Paid in Capital | $276.1m | $295.0m | $369.6m | $388.4m | $409.3m | $434.3m | $408.1m | $439.5m | $479.4m | $543.8m | |
| Retained Earnings (Accumulated Deficit) | ($84.3m) | ($26.8m) | $86.5m | $199.5m | $326.5m | $379.9m | $481.2m | $482.6m | $556.4m | $517.9m | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($134k) | ($747k) | ($3.2m) | $7.4m | $9.0m | $1.5m | ($3.2m) | ($593k) | ($189k) | ($44k) | |
| Stockholders' Equity Attributable to Parent | $191.8m | $267.5m | $453.0m | $595.4m | $744.9m | $815.9m | $886.2m | $921.5m | $1.0b | $1.1b | |
| Liabilities and Equity | $309.6m | $424.5m | $977.8m | $1.2b | $1.5b | $1.7b | $1.7b | $1.3b | $1.4b | $1.5b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.